Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02923739
Title Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

ovary epithelial cancer

fallopian tube cancer

peritoneum cancer

Therapies

Bevacizumab + Emactuzumab + Paclitaxel

Bevacizumab + Paclitaxel

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.